Schoenherr has advised AI ophthalmology spin-off RetInSight and its founding shareholders on the sale to Topcon Healthcare. Dorda reportedly advised Topcon Healthcare.
Topcon Healthcare is part of Topcon Corporation.
According to Schoenherr, RetInSight’s vendor-neutral AI platform, developed at the Medical University of Vienna, analyses OCT scans to detect and monitor major retinal diseases and is already commercialized across Europe. Through this acquisition, Topcon will integrate RetInSight’s algorithms into its “Healthcare from the Eye” ecosystem and scale the solution globally, strengthening its clinical-care, drug-discovery, and therapeutic offerings.
The Schoenherr team included Partners Thomas Kulnigg, Marco Thorbauer, and Christoph Haid, Counsel Karin Pusch, Attorneys at Law Dominik Tyrybon, Clemens Pretscher, Daniela Birnbauer, Tobias Hayden, Daniel Komarek, and Theresa Dabsch, and Associates Maximilian Czernin, Alexander Giehser, Sarah Draexler, and Lukas Lobinger.
Editor's Note: After this article was published, Dorda announced it advised Topcon. The firm's team included Partners Lukas Herrmann and Bernhard Rieder, Principal Associate Denise Runceanu, and Associate Bianca Schamberger.